Abstract
In the course of development of new drugs there is a tendency to think and plan, on both conscious and unconscious levels, on the basis of the experience with existing therapeutics. Often, therefore, the development of new antidepressants has been based on knowledge collected with tricyclic antidepressants or MAO inhibitors. The experimental pharmacodynamics of tricyclics in particular has played a dominant role in the development of models for the mode of action of antidepressants and hence in the development of rational drugs with selective effects. On the clinical side our planning is also influenced by earlier experience, when side effects are recorded or when pharmacokinetic studies are designed, for example. Our experience with earlier drugs should be the inspiration and not the limitation of our research on new compounds. What we must do, then, is distil the essence of the earlier experience that can be expected to be relevant for the new drugs.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Abernethy DR, Greenblatt DJ, Shader RI (1985) Imipramine and desipramine disposition in the elderly. J Pharmacol Exp Ther 232: 183–188
Bertram U, Kragh-Sorensen P, Rafaelsen OJ, Larsen NE (1979) Saliva secretion following long-term antidepressant treatment with nortriptyline controlled by plasma levels. Scand J Dent Res 87: 58–64
Bjerre M, Gram LF, Kragh-Sorensen P, Kristensen CB, Pedersen OL, Moller M, Thayssen P (1981) Dose-dependent kinetics of imipramine in elderly patients. Psychopharmacology (Berlin) 75: 354–357
Brosen K, Otton SY, Gram LF (1985) Sparteine oxidation polymorphism in Denmark. Acta Pharmacol Toxicol 57: 357–360
Brosen K, Gram LF, Klysner R, Bech P (1986) Imipramine and its metabolites during steady-state: significance of dose-dependent kinetics. Eur J Clin Pharmacol 30: 43–49
Gram LF (1977 a) Factors influencing the metabolism of tricyclic antidepressants. Studies on interactions and first pass elimination. Dan Med Bull 24: 81–88
Gram LF (1977 b) Plasma level monitoring of tricyclic antidepressants. Clin Pharmacokinet 2:237–251
Gram LF (1983) Antidepressants: receptors, pharmacokinetics and clinical effects. In: Burrows GD, Norman T, Davis B (eds) Antidepressants. Elsevier/North-Holland, Amsterdam, pp 81–96 (Drugs and psychiatry, vol 1 )
Gram LF, Reisby N, Ibsen I, Nagy A, Dencker SJ, Bech P, Petersen GO, Christiansen J (1976) Plasma levels and antidepressive effect of imipramine. Clin Pharmacol Ther 19: 318–324
Gram LF, Sondergaard I, Christiansen J, Petersen GO, Bech P, Reisby N, Ibsen I, Ortmann J, Nagy A, Dencker SJ, Jacobsen O, Krautwald O (1977) Steady state kinetics of imipramine in patients. Psychopharmacology (Berlin) 54: 255–261
Gram LF, Pedersen OL, Kristensen CB, Bjerre M, Kragh-Sorensen P (1982) Drug level monitoring in psychopharmacology: usefulness and clinical problems, with special reference to tricyclic antidepressants. Ther Drug Monit 4: 17–25
Gram LF, Bjerre M, Kragh-Sorensen P, Kvinesdal B, Molin J, Pedersen OL, Reisby N (1983) Imipramine metabolites in blood of patients during therapy and after overdose. Clin Pharmacol Ther 33: 335–342
Hall H (1983) Relationships between receptor affinities of different antidepressants and their clinical profiles. In: Gram LF, Usdin E, Dahl SG, Kragh-Sorensen P, Sjöqvist F, Morselli PL (eds) Clinical pharmacology in psychiatry, bridging the experimental therapeutic gap. Macmillan, London, pp 251–267
Hall H, Ogren SO (1981) Effects of antidepressant drugs on different receptors in the brain. Eur J Pharmacol 70: 393–407
Kragh-Sorensen P (1978) Correlation between plasma levels of nortriptyline and clinical effects. Psychopharmacology (Berlin) 2: 451–456
Kragh-Sorensen P, Larsen NE (1980) Factors influencing nortriptyline steady-state kinetics: plasma and saliva levels. Clin Pharmacol Ther 28: 796–803
Kristensen CB (1983) Serum protein binding of imipramine in healthy subjects. Clin Pharmacol Ther 34: 689–694
Langer SZ, Briley MS, Raisman R, Henry JF, Morselli PL (1980) Specific 3H-imipramine binding in human platelets. Naunyn-Schmiedebergs Arch Pharmacol 313: 189–194
Langer SZ, Raisman R, Briley M (1981) High-affinity 3H-DMI binding is associated with neuronal noradrenaline uptake in the periphery and the central nervous system. Eur J Pharmacol 72: 423–424
Nielsen JR, Johansen T, Arentoft A, Gram LF (1983) Effects of imipramine on the orthostatic changes in blood pressure, heart rate and plasma catecholamines. Clin Exp Pharmacol Physiol 10: 497–503
Paul SM, Rehavi M, Rice KC, Ittah Y, Skolnick P (1981) Does high affinity 3H-imipramine binding label serotonin reuptake sites in brain and platelets? Life Sci 28: 2753–2760
Pedersen OL, Gram LF, Kristensen CB, Møller M, Thayssen P, Bjerre M, Kragh-Sørensen P, Klitgaard NA, Sindrup E, Hole P, Brinkkfv M (1982) Overdosage of antidepressants: clinical and pharmacokinetic aspects. Eur J Clin Pharmacol 23: 513–521
Rehavi M, Skolnick P, Hulihan B, Paul SM (1981) High affinity binding of 3H-desipramine to rat cerebral cortex: relationship to tricyclic antidepressant-induced inhibition of norepinephrine uptake. Eur J Pharmacol 70: 597–599
Rehavi M, Tracer H, Rice K, Skolnick P, Paul SM (1983) 3H-2-nitroimipramine: a selective “slowly-dissociating” probe of the imipramine binding site (“serotonin transporter”) in platelets and brain. Life Sci 32: 645–653
Richelson E (1983) Antidepressants: effects on histaminic and muscarinic receptors. In: Gram LF, Usdin E, Dahl SG, Kragh-Sørensen P, Sjoqvist F, Morselli PL (eds) Clinical pharmacology in psychiatry, bridging the experimental therapeutic gap. Macmillan, London, pp 288–300
Richelson E, Pfenning M (1984) Blockade by antidepressants and related compounds of biogenic amine uptake in to rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol 104: 277–286
Tang SW, Seeman P (1980) Effect of antidepressant drugs on serotonergic and adrenergic receptors. Naunyn-Schmiedebergs Arch Pharmacol 311: 255–261
Thayssen P, Bjerre M, Kragh-Sorensen P, Moller M, Pedersen OL, Kristensen CB, Gram LF (1981) Cardiovascular effects of imipramine and nortriptyline in elderly patients. Psycho-pharmacology (Berlin) 74: 360–364
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Gram, L.F., Brøsen, K., Christensen, P., Kragh-Sørensen, P. (1987). Pharmacokinetic Considerations Relevant to the Pharmacodynamics of Antidepressants. In: Dahl, S.G., Gram, L.F., Paul, S.M., Potter, W.Z. (eds) Clinical Pharmacology in Psychiatry. Psychopharmacology Series, vol 3. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-71288-3_22
Download citation
DOI: https://doi.org/10.1007/978-3-642-71288-3_22
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-71290-6
Online ISBN: 978-3-642-71288-3
eBook Packages: Springer Book Archive